Anastasios John Kanellopoulos1, George Asimellis2. 1. From Laservision.gr Eye Institute (Kanellopoulos, Asimellis), Athens, Greece; New York University Medical School (Kanellopoulos), New York, New York, USA. Electronic address: ajk@brilliantvision.com. 2. From Laservision.gr Eye Institute (Kanellopoulos, Asimellis), Athens, Greece; New York University Medical School (Kanellopoulos), New York, New York, USA.
Abstract
PURPOSE: To evaluate the safety, efficacy, and refractive and keratometric stability of myopic femtosecond laser in situ keratomileusis (LASIK) with concurrent prophylactic high-fluence corneal collagen crosslinking (CXL) compared with the outcomes of standard femtosecond LASIK. SETTING: Private clinical practice, Athens, Greece. DESIGN: Consecutive randomized prospective comparative study. METHODS: Eyes that had myopic LASIK or myopic LASIK with concurrent high-fluence CXL were evaluated preoperatively and up to 2 years postoperatively for manifest refraction spherical equivalent (MRSE), refractive astigmatism, visual acuity, corneal keratometry (K), and endothelial cell count. RESULTS:One hundred forty consecutive eyes had myopic LASIK; 65 of the eyes were treated additionally withCXL. In the LASIK-CXL eyes, the mean postoperative MRSE was -0.18 diopter (D) ± 17.0 (SD) from -6.67 ± 2.14 D preoperatively. The postoperative flat K was 37.67 D from 43.92 D, and the steep K was 38.38 D from 45.15 D. The correlation coefficient of SE correction predictability was 0.975. In the LASIK-only eyes, the mean postoperative MRSE was -0.32 ± 0.24 D from -5.49 ± 1.99 D preoperatively. The flat K was 38.04 D from 43.15 D, and the steep K was 38.69 D from 44.03 D. The correlation coefficient of SE correction predictability was 0.968. The differences between the 2 groups at the 20/20 and 20/25 levels were statistically significant (P = .045 and P = .039, respectively). CONCLUSION: Two-year results indicate that the application of prophylactic CXL concurrently with high-myopic LASIK appears to improve refractive and keratometric stability, presumably by affecting corneal biomechanical properties. FINANCIAL DISCLOSURE: Dr. Kanellopoulos is a consultant to Alcon Surgical, Inc., Wavelight Laser Technologie AG, Allergan, Inc., Avedro, Inc., and i-Optics Corp. Dr. Asimellis has no financial or proprietary interest in any material or method mentioned.
RCT Entities:
PURPOSE: To evaluate the safety, efficacy, and refractive and keratometric stability of myopic femtosecond laser in situ keratomileusis (LASIK) with concurrent prophylactic high-fluence corneal collagen crosslinking (CXL) compared with the outcomes of standard femtosecond LASIK. SETTING: Private clinical practice, Athens, Greece. DESIGN: Consecutive randomized prospective comparative study. METHODS: Eyes that had myopic LASIK or myopic LASIK with concurrent high-fluence CXL were evaluated preoperatively and up to 2 years postoperatively for manifest refraction spherical equivalent (MRSE), refractive astigmatism, visual acuity, corneal keratometry (K), and endothelial cell count. RESULTS: One hundred forty consecutive eyes had myopic LASIK; 65 of the eyes were treated additionally with CXL. In the LASIK-CXL eyes, the mean postoperative MRSE was -0.18 diopter (D) ± 17.0 (SD) from -6.67 ± 2.14 D preoperatively. The postoperative flat K was 37.67 D from 43.92 D, and the steep K was 38.38 D from 45.15 D. The correlation coefficient of SE correction predictability was 0.975. In the LASIK-only eyes, the mean postoperative MRSE was -0.32 ± 0.24 D from -5.49 ± 1.99 D preoperatively. The flat K was 38.04 D from 43.15 D, and the steep K was 38.69 D from 44.03 D. The correlation coefficient of SE correction predictability was 0.968. The differences between the 2 groups at the 20/20 and 20/25 levels were statistically significant (P = .045 and P = .039, respectively). CONCLUSION: Two-year results indicate that the application of prophylactic CXL concurrently with high-myopic LASIK appears to improve refractive and keratometric stability, presumably by affecting corneal biomechanical properties. FINANCIAL DISCLOSURE: Dr. Kanellopoulos is a consultant to Alcon Surgical, Inc., Wavelight Laser Technologie AG, Allergan, Inc., Avedro, Inc., and i-Optics Corp. Dr. Asimellis has no financial or proprietary interest in any material or method mentioned.
Authors: Samantha M Bradford; Eric R Mikula; Dongyul Chai; Donald J Brown; Tibor Juhasz; James V Jester Journal: Biomed Opt Express Date: 2017-09-29 Impact factor: 3.732
Authors: Marcus Ang; Damien Gatinel; Dan Z Reinstein; Erik Mertens; Jorge L Alió Del Barrio; Jorge L Alió Journal: Eye (Lond) Date: 2020-07-24 Impact factor: 3.775
Authors: Aris Konstantopoulos; Yu-Chi Liu; Ericia P Teo; Chan L Nyein; Gary H Yam; Jodhbir S Mehta Journal: Transl Vis Sci Technol Date: 2019-05-20 Impact factor: 3.283
Authors: Rajesh K Rajpal; Christine B Wisecarver; Dawn Williams; Sachin D Rajpal; Rhonda Kerzner; Nick Nianiaris; Grace Lytle; Khoa Hoang Journal: Ophthalmol Ther Date: 2015-10-26